Do analysts prefer OBSV or MIRA?

MIRA Pharmaceuticals has a consensus target price of $3.50, indicating a potential upside of 308.07%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation & earnings, OBSV or MIRA?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is OBSV or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% MIRA Pharmaceuticals N/A -106.95% -104.18%

Do analysts recommend OBSV or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, OBSV or ABVC?

ABVC BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A ABVC BioPharma N/A N/A -$7.91M -$0.30 N/A

Is OBSV or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% ABVC BioPharma N/A -47.68% -30.97%

Is OBSV or CPHI more profitable?

ObsEva has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% China Pharma -85.56% -63.93% -31.42%

Do analysts recommend OBSV or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, OBSV or TAOX?

Synaptogenix has higher revenue and earnings than ObsEva. Synaptogenix is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Synaptogenix $300K 107.71 -$28.74M -$3.85 N/A

Is OBSV or TAOX more profitable?

ObsEva has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Synaptogenix -2,153.97% -128.51% -97.54%

Do analysts recommend OBSV or OPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, OBSV or OPTH?

Optimi Health has higher revenue and earnings than ObsEva. Optimi Health is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Optimi Health $175.67K 161.67 -$1.12M -$0.76 N/A

Is OBSV or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Optimi Health N/A N/A N/A

ObsEva (OBSV) Competitors

$0.0001 +0.00 (+10,000.00%)

As of 09/22/2026

Compare

OBSV vs. MIRA, ABVC, CPHI, TAOX, and OPTH

Should you buy ObsEva stock or one of its competitors? ObsEva's main competitors and comparable companies include MIRA Pharmaceuticals (MIRA), ABVC BioPharma (ABVC), China Pharma (CPHI), Synaptogenix (TAOX), and Optimi Health (OPTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ObsEva compare to MIRA Pharmaceuticals?

ObsEva (NASDAQ:OBSV) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, MIRA Pharmaceuticals had 4 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for MIRA Pharmaceuticals and 0 mentions for ObsEva. MIRA Pharmaceuticals' average media sentiment score of 0.17 beat ObsEva's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
MIRA Pharmaceuticals	Neutral

17.5% of ObsEva shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MIRA Pharmaceuticals' return on equity of -106.95% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

MIRA Pharmaceuticals has a consensus target price of $3.50, indicating a potential upside of 308.07%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

Summary

MIRA Pharmaceuticals beats ObsEva on 10 of the 13 factors compared between the two stocks.

How does ObsEva compare to ABVC BioPharma?

ObsEva (NASDAQ:OBSV) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

ABVC BioPharma's return on equity of -47.68% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
ABVC BioPharma	N/A	-47.68%	-30.97%

ABVC BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.30	N/A

In the previous week, ObsEva's average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
ABVC BioPharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ABVC BioPharma beats ObsEva on 6 of the 9 factors compared between the two stocks.

How does ObsEva compare to China Pharma?

ObsEva (NASDAQ:OBSV) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

China Pharma has higher revenue and earnings than ObsEva. China Pharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
China Pharma	$3.91M	7.75	-$3.08M	-$0.43	N/A

In the previous week, ObsEva's average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
China Pharma	Neutral

17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ObsEva has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

China Pharma beats ObsEva on 6 of the 10 factors compared between the two stocks.

How does ObsEva compare to Synaptogenix?

ObsEva (NASDAQ:OBSV) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Synaptogenix has higher revenue and earnings than ObsEva. Synaptogenix is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Synaptogenix	$300K	107.71	-$28.74M	-$3.85	N/A

ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

17.5% of ObsEva shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Synaptogenix	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ObsEva has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

Summary

ObsEva beats Synaptogenix on 6 of the 11 factors compared between the two stocks.

How does ObsEva compare to Optimi Health?

ObsEva (NASDAQ:OBSV) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Optimi Health's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Optimi Health	N/A	N/A	N/A

Optimi Health has higher revenue and earnings than ObsEva. Optimi Health is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Optimi Health	$175.67K	161.67	-$1.12M	-$0.76	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Optimi Health had 5 more articles in the media than ObsEva. MarketBeat recorded 5 mentions for Optimi Health and 0 mentions for ObsEva. Optimi Health's average media sentiment score of 0.19 beat ObsEva's score of 0.00 indicating that Optimi Health is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
Optimi Health	Neutral

Summary

Optimi Health beats ObsEva on 8 of the 11 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8K	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	0.00	792.28	274.10	25.70
Price / Sales	N/A	857.09	672.61	90.85
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.00	10.57	10.48	6.32
Net Income	-$58.38M	$2.81B	$3.49B	$359.73M
7 Day Performance	N/A	-0.17%	-0.68%	0.17%
1 Month Performance	N/A	-1.39%	-3.18%	-3.27%
1 Year Performance	N/A	2.83%	15.13%	5.58%

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	$0.00 +10,000.0%	N/A	N/A	$8K	N/A	N/A	50
MIRA MIRA Pharmaceuticals	2.4314 of 5 stars	$0.75 +4.8%	$3.50 +364.2%	-34.0%	$31.64M	N/A	N/A	2	Gap Up
ABVC ABVC BioPharma	0.1345 of 5 stars	$1.18 +8.8%	N/A	-60.7%	$31.31M	$510K	N/A	30	Gap Up
CPHI China Pharma	N/A	$0.72 -0.8%	N/A	-64.0%	$31.02M	$3.91M	N/A	250
TAOX Synaptogenix	0.0905 of 5 stars	$4.02 +8.7%	N/A	-24.1%	$30.11M	$300K	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. MIRA, ABVC, CPHI, TAOX, and OPTH

How does ObsEva compare to MIRA Pharmaceuticals?

Summary

How does ObsEva compare to ABVC BioPharma?

Summary

How does ObsEva compare to China Pharma?

Summary

How does ObsEva compare to Synaptogenix?

Summary

How does ObsEva compare to Optimi Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. MIRA, ABVC, CPHI, TAOX, and OPTH

How does ObsEva compare to MIRA Pharmaceuticals?

Which has more risk and volatility, OBSV or MIRA?

Does the media prefer OBSV or MIRA?

Do insiders and institutionals have more ownership in OBSV or MIRA?

Is OBSV or MIRA more profitable?

Do analysts prefer OBSV or MIRA?

Which has better valuation & earnings, OBSV or MIRA?

Summary

How does ObsEva compare to ABVC BioPharma?

Which has more volatility & risk, OBSV or ABVC?

Is OBSV or ABVC more profitable?

Which has preferable earnings and valuation, OBSV or ABVC?

Does the media prefer OBSV or ABVC?

Do analysts recommend OBSV or ABVC?

Do institutionals & insiders have more ownership in OBSV or ABVC?

Summary

How does ObsEva compare to China Pharma?

Which has more risk & volatility, OBSV or CPHI?

Which has better earnings & valuation, OBSV or CPHI?

Does the media prefer OBSV or CPHI?

Do insiders & institutionals believe in OBSV or CPHI?

Is OBSV or CPHI more profitable?

Summary

How does ObsEva compare to Synaptogenix?

Which has better earnings & valuation, OBSV or TAOX?

Which has more volatility and risk, OBSV or TAOX?

Do insiders and institutionals have more ownership in OBSV or TAOX?

Does the media favor OBSV or TAOX?

Do analysts recommend OBSV or TAOX?

Is OBSV or TAOX more profitable?

Summary

How does ObsEva compare to Optimi Health?

Is OBSV or OPTH more profitable?

Which has stronger earnings and valuation, OBSV or OPTH?

Do analysts recommend OBSV or OPTH?

Do institutionals & insiders have more ownership in OBSV or OPTH?

Does the media refer more to OBSV or OPTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools